Stockscreener 앱 받기
40.72
4.99%
-2.14
전일 마감가:
$42.86
열려 있는:
$43.32
하루 거래량:
1.90M
Relative Volume:
1.47
시가총액:
$3.87B
수익:
$47.30M
순이익/손실:
$-225.97M
주가수익비율:
-17.33
EPS:
-2.35
순현금흐름:
$-188.86M
1주 성능:
+8.76%
1개월 성능:
+12.11%
6개월 성능:
-5.59%
1년 성능:
+365.37%
1일 변동 폭
$40.38
$43.97
1주일 범위
$36.91
$43.97
52주 변동 폭
$6.76
$46.98
Scholar Rock Holding Corp Stock (SRRK) Company Profile
명칭
Scholar Rock Holding Corp
전화
857-259-3860
주소
301 BINNEY STREET, CAMBRIDGE, MA
SRRK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
40.72 | 3.55B | 47.30M | -225.97M | -188.86M | -2.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-26 | 재확인 | H.C. Wainwright | Buy |
| 2024-10-07 | 재확인 | H.C. Wainwright | Buy |
| 2024-03-28 | 개시 | Raymond James | Strong Buy |
| 2023-10-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-04-03 | 재개 | Piper Sandler | Overweight |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-07-12 | 개시 | Truist | Buy |
| 2022-03-23 | 개시 | H.C. Wainwright | Buy |
| 2021-12-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | Credit Suisse | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-03-12 | 개시 | Robert W. Baird | Outperform |
모두보기
Scholar Rock Holding Corp 주식(SRRK)의 최신 뉴스
M&T Bank Corp Sells 489 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) - Defense World
What drives Scholar Rock Holding Corporation stock priceSuperior returns - Jammu Links News
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Scholar Rock Holding Corporation Stock Analysis and ForecastUnstoppable profit momentum - Jammu Links News
Use AI to optimize your outbound sales efforts by targeting the right prospectsFree Premium Stock Market Reports - Newser
Scholar Rock (NASDAQ:SRRK) Coverage Initiated by Analysts at Cantor Fitzgerald - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives $42.67 Average PT from Brokerages - MarketBeat
What makes Scholar Rock Holding Corporation stock price move sharplyFree AI-Powered Stock Predictions - Newser
How Scholar Rock Holding Corporation stock performs during market volatilityCapital Preservation Investment Ideas - Newser
Why Scholar Rock Holding Corporation stock attracts strong analyst attentionSafe Entry High Exit Alerts - Newser
How Alarum Technologies Ltd. Depositary Receipt stock performs during market volatilitySecure Your Capital Strategy - Newser
Scholar Rock (NASDAQ:SRRK) Trading Up 6.5%What's Next? - MarketBeat
Scholar Rock CSO Mo Qatanani sells $828,898 in shares By Investing.com - Investing.com Nigeria
High Growth Tech Stocks To Watch In US July 2025 - Yahoo Finance
Scholar Rock CSO Mo Qatanani sells $828,898 in shares - Investing.com Australia
Insider Sell: Mo Qatanani Sells 24,066 Shares of Scholar Rock Ho - GuruFocus
Scholar Rock Q1 2025 slides: apitegromab advances toward FDA approval with priority review - Investing.com Nigeria
Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 3000E Value Index - MarketScreener
Scholar Rock (NASDAQ:SRRK) Trading Up 5.2%Here's What Happened - MarketBeat
Truist reiterates buy rating on Scholar Rock stock amid SMA therapy potential - Investing.com Nigeria
Is Scholar Rock Holding Corp. overvalued or undervalued? - MarketsMojo
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Abbott Laboratories (ABT) - The Globe and Mail
Syncona restructures biotech fund; Lilly’s $1B Verve bet; FDA’s two-track future — a BioCentury podcast - biocentury.com
Scholar Rock's Breakthrough SMA Drug Shows Positive Phase 3 Results, FDA Fast-Tracks Review - Stock Titan
Scholar Rock (NASDAQ:SRRK) Trading Down 5.7% – Time to Sell? - Defense World
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
SG Americas Securities LLC Increases Position in Scholar Rock Holding Corporation (NASDAQ:SRRK) - Defense World
Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial - Insider Monkey
Scholar Rock (NASDAQ:SRRK) Receives Outperform Rating from Wedbush - MarketBeat
Why Scholar Rock Shares Are Soaring Today - The Globe and Mail
Scholar Rock (NASDAQ:SRRK) Shares Gap UpWhat's Next? - MarketBeat
Transcript : Scholar Rock Holding CorporationSpecial Call - MarketScreener
Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results - Yahoo Finance
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study - Benzinga
Scholar Rock stock soars after drug shows promise in preserving lean mass during weight loss - Investing.com Australia
Trading Day Triumph: Scholar Rock Holding Corp (SRRK) Ends at 31.15, a -3.05 Surge/Plunge - DWinneX
Scholar Rock's drug helps Zepbound patients retain more muscle in trial - marketscreener.com
Scholar Rock (SRRK) Surges 14% Following EMBRAZE Trial Results | SRRK Stock News - GuruFocus
Scholar Rock (SRRK) Surges After Promising Weight Loss Trial - GuruFocus
Scholar Rock Reports Positive Results From Phase 2 EMBRAZE Study - Nasdaq
Scholar Rock stock gains on weight loss data (SRRK:NASDAQ) - Seeking Alpha
Scholar Rock (SRRK) Reveals Phase 2 Trial Success of Apitegromab with Tirzepatide | SRRK Stock News - GuruFocus
Scholar Rock's drug helps patients on Zepbound preserve muscle in trial - MarketScreener
Scholar Rock’s apitegromab preserves lean mass during weight loss - Investing.com
Scholar Rock's drug helps preserve lean mass in mid-stage trial - marketscreener.com
Scholar Rock's Breakthrough Drug Shows 55% Better Muscle Preservation in Weight Loss Study - Stock Titan
Notable Two Hundred Day Moving Average CrossSRRK - Nasdaq
Scholar Rock Holding Corp Executives Sell Shares to Cover Tax Obligations - TradingView
GAMMA Investing LLC Buys 30,140 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) - MarketBeat
GAMMA Investing LLC Has $962,000 Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Scholar Rock Holding Corp (SRRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Scholar Rock Holding Corp 주식 (SRRK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER |
Jul 08 '25 |
Sale |
34.44 |
24,066 |
828,898 |
115,495 |
0.59%
0.34%
자본화:
|
볼륨(24시간):